PolyPid Announces Recruitment of First Patient in Revised SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for Prevention of Abdominal Colorectal Surgical Site Infections

PolyPid Ltd. has recruited the first patient in its revised SHIELD II Phase 3 trial for D-PLEX100, a late-stage biopharma product aimed at preventing abdominal colorectal surgical site infections. The US Food and Drug Administration recently accepted the company’s revised protocol for the study, which will enroll an estimated 550 patients undergoing colorectal resection surgery with large incisi..